Our results suggest that ML210 promote PEX10 expression and lead to the elimination of ROS in prostate cancer, while enzalutamide could inhibit PEX10 function and synergy with ML210 to exert a better anti-tumor effect. This evidence concerns the gene PEX10 and Familial prostate cancer.